Overexpression of the JmjC Histone Demethylase KDM5B in Human Carcinogenesis: Involvement in the Proliferation of Cancer Cells Through the E2F/RB Pathway

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2010 Mar 16

PMID 20226085

Citations 111

Authors

Shinya Hayami

Masanori Yoshimatsu

Abhimanyu Veerakumarasivam

Motoko Unoki

Yukiko Iwai

Tatsuhiko Tsunoda

Helen I Field

John D Kelly

David E Neal

Hiroki Yamaue

Bruce A J Ponder

Yusuke Nakamura

Ryuji Hamamoto

Affiliations

Soon will be listed here.

Abstract

Background: Although an increasing number of histone demethylases have been identified and biochemically characterized, their biological functions largely remain uncharacterized, particularly in the context of human diseases such as cancer. We investigated the role of KDM5B, a JmjC histone demethylase, in human carcinogenesis. Quantitative RT-PCR and microarray analyses were used to examine the expression profiles of histone demethylases in clinical tissue samples. We also examined the functional effects of KDM5B on the growth of cancer cell lines treated with small interfering RNAs (siRNAs). Downstream genes and signal cascades induced by KDM5B expression were identified from Affymetrix Gene Chip experiments, and validated by real-time PCR and reporter assays. Cell cycle-dependent characteristics of KDM5B were identified by immunofluorescence and FACS.

Results: Quantitative RT-PCR analysis confirmed that expression levels of KDM5B are significantly higher in human bladder cancer tissues than in their corresponding non-neoplastic bladder tissues (P < 0.0001). The expression profile analysis of clinical tissues also revealed up-regulation of KDM5B in various kinds of malignancies. Transfection of KDM5B-specific siRNA into various bladder and lung cancer cell lines significantly suppressed the proliferation of cancer cells and increased the number of cells in sub-G1 phase. Microarray expression analysis indicated that E2F1 and E2F2 are downstream genes in the KDM5B pathway.

Conclusions: Inhibition of KDM5B may affect apoptosis and reduce growth of cancer cells. Further studies will explore the pan-cancer therapeutic potential of KDM5B inhibition.

Citing Articles

Molecular insight into histone methylation as a novel target for oral squamous cell carcinoma: future hope in personalised medicine.

Rajendran P, Prasad M, Ali E, Sekar R, Alzahrani A, Karobari M J Cancer. 2025; 16(5):1575-1590.

PMID: 39991574 PMC: 11843246. DOI: 10.7150/jca.103243.

Current advances and future directions in targeting histone demethylases for cancer therapy.

Shin J, Yoo H, Roe J Mol Cells. 2025; 48(3):100192.

PMID: 39938867 PMC: 11889978. DOI: 10.1016/j.mocell.2025.100192.

Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis.

Ma L, Zhang J, Dai Z, Liao P, Guan J, Luo Z Front Immunol. 2025; 15:1512349.

PMID: 39872524 PMC: 11770037. DOI: 10.3389/fimmu.2024.1512349.

The emerging roles of histone demethylases in cancers.

Tong D, Tang Y, Zhong P Cancer Metastasis Rev. 2024; 43(2):795-821.

PMID: 38227150 DOI: 10.1007/s10555-023-10160-9.

Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma.

Kato H, Hayami S, Ueno M, Suzaki N, Nakamura M, Yoshimura T Cancer Sci. 2023; 115(2):385-400.

PMID: 38082550 PMC: 10859612. DOI: 10.1111/cas.16038.

References

Muller H, Helin K . The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta. 2000; 1470(1):M1-12. DOI: 10.1016/s0304-419x(99)00030-x. View

Klose R, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P . The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 2006; 442(7100):312-6. DOI: 10.1038/nature04853. View

Nevins J . The Rb/E2F pathway and cancer. Hum Mol Genet. 2001; 10(7):699-703. DOI: 10.1093/hmg/10.7.699. View

Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R . Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res. 2001; 61(9):3544-9. View

Schneider R, Bannister A, Kouzarides T . Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci. 2002; 27(8):396-402. DOI: 10.1016/s0968-0004(02)02141-2. View

Gorgoulis V, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D . Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 2002; 198(2):142-56. DOI: 10.1002/path.1121. View

Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G . Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2002; 199(1):41-9. DOI: 10.1002/path.1252. View

Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S . Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003; 22(14):2192-205. DOI: 10.1038/sj.onc.1206288. View

Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K . Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004; 23(13):2385-400. DOI: 10.1038/sj.onc.1207392. View

10.

Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, Fukunaga A . Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus. 2004; 17(2):150-4. DOI: 10.1111/j.1442-2050.2004.00393.x. View

11.

Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R . E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 2004; 23(33):5616-23. DOI: 10.1038/sj.onc.1207749. View

12.

Foster C, Falconer A, Dodson A, Norman A, Dennis N, Fletcher A . Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004; 23(35):5871-9. DOI: 10.1038/sj.onc.1207800. View

13.

Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva F, Li M . SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6(8):731-40. DOI: 10.1038/ncb1151. View

14.

Unoki M, Nishidate T, Nakamura Y . ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004; 23(46):7601-10. DOI: 10.1038/sj.onc.1208053. View

15.

Johnson D, Schwarz J, Cress W, Nevins J . Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993; 365(6444):349-52. DOI: 10.1038/365349a0. View

16.

DeGregori J, Leone G, Ohtani K, Miron A, Nevins J . E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 1995; 9(23):2873-87. DOI: 10.1101/gad.9.23.2873. View

17.

Klose R, Kallin E, Zhang Y . JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006; 7(9):715-27. DOI: 10.1038/nrg1945. View

18.

Sparmann A, van Lohuizen M . Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-56. DOI: 10.1038/nrc1991. View

19.

Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G . Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res. 2007; 13(1):144-51. DOI: 10.1158/1078-0432.CCR-06-0780. View

20.

Kubicek S, OSullivan R, August E, Hickey E, Zhang Q, Teodoro M . Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007; 25(3):473-81. DOI: 10.1016/j.molcel.2007.01.017. View